Ph.D. Noubar B. Afeyan - 31 Dec 2021 Form 5 Insider Report for Moderna, Inc. (MRNA)

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRNA	Common Stock	Gift	$0	-100,000	-4.3%	$0.000000	2,238,970	11 Aug 2021	Direct	F1
holding	MRNA	Common Stock						6,116,657	31 Dec 2021	By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P.	F2
holding	MRNA	Common Stock						11,464,359	31 Dec 2021	By Flagship VentureLabs IV LLC and Flagship Pioneering, Inc.	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Includes shares received in prior distributions-in-kind from Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.
F2	3,276,339 shares are held directly by Flagship Fund IV and 2,840,318 shares are held directly by Flagship Fund IV-Rx. Flagship Ventures Fund IV General Partners LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F3	11,460,435 shares are held directly by Flagship VentureLabs IV LLC ("VentureLabs IV") and 3,924 shares are held directly by Flagship Pioneering, Inc. ("Flagship Pioneering"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. The reporting person is the sole manager of Flagship Fund IV GP and CEO and sole stockholder of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.